Joshua K. Sabari, MD | Authors


First-Line Treatment Paradigm of NSCLC and the Advent of Immunotherapy

December 07, 2022

Joshua Sabari, MD, a thoracic medical oncologist at NYU Langone Health Perlmutter Cancer Center in New York, NY reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.

A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy

November 14, 2022

In the first installment of this series, Joshua Sabari, MD, provides an overview on the use of chemotherapy for first-line treatment of NSCLC, and discusses how the more recent availability of PD-1/PD-L1– and CTLA-4–targeted immunotherapy is changing the field.